EMA: Draft product-specific guidances ♬ [Regulatives / Guidelines]

posted by pash413 – India, 2013-12-18 13:35 (4576 d 13:37 ago) – Posting: # 12073
Views: 31,106

Dear All
Wondering about the Imatinib product specific guideline where BE criteria suggested is AUC72 and Cmax.
However as per SPC halflife is 18 hours and literature shows halflife around 16 hours in healthy subjects. In few subjects at 72.0 hour concentration is zero.

What is the criteria set by EMEA for long half life drugs. :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
296 visitors (0 registered, 296 guests [including 28 identified bots]).
Forum time: 04:13 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5